Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan
Open accessThe DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
Background: As human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a rare chronic neurological disease, large scale studies to collect continuous clinical data have been difficult to conduct. Therefore, the incidence of comorbidities and drug utilization data remain unknown. When conducting trials to develop new drugs in rare disease such as HAM/TSP, historical control data obtained from registry studies would be useful, as cohorts in rare disease tend to be small. Long-term follow-up of patients with a chronic disease can also be challenging. In this study, we addressed the following two goals using registry data on patients (n = 486) enrolled in the Japanese HAM/TSP patient registry “HAM-net” from 2012 to 2016: 1) to clarify the epidemiological information of HAM/TSP such as the incidence of comorbidities and drug utilization and 2) to provide the real-world data on changes in lower limb motor dysfunction. Results: In HAM-net-registered patients, common comorbidities were fractures, herpes zoster, and uveitis, with incidences of 55.5, 10.4, and 6.5, respectively, per 1000 person-years. Every year, oral steroid treatment was administered in 48.2–50.7% of the HAM-net-registered patients and interferon-α treatment was used in 2.6–3.5% of patients. The median dose of oral prednisolone was low at 5.0 mg/day. The incidence of fractures and herpes zoster tended to be higher in the steroid-treated group than in the untreated group (fractures: 61.0 vs. 48.3, herpes zoster: 12.7 vs. 8.8, per 1000 person-years). The analysis of chronological change in Osame motor disability score (OMDS) indicated that the mean change in OMDS was + 0.20 [95% confidence intervals (CI): 0.14–0.25] per year in the one-year observation group (n = 346) and + 0.57 (95% CI: 0.42–0.73) over four years in the four-year observation group (n = 148). Significant deterioration of OMDS was noted in all subgroups with varying steroid use status. Conclusions: This study revealed the incidence of comorbidities and drug utilization data in patients with HAM/TSP using registry data. Furthermore, this study provided real-world data on chronological changes in lower limb motor dysfunction in patients with HAM/TSP, indicating the utility of these data as historical controls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The three most characterised classes of DMTs for HAM are antiretrovirals, corticosteroids, and IFN-a [232].”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [232]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The combination of randomized and historical controls in clinical trials
Pocock, S. J. (1976) · Journal of Chronic Diseases · doi:10.1016/0021-9681(76)90044-8 · Cited by 514
Use of historical control data for assessing treatment effects in clinical trials
Viele, K., Berry, S., Neuenschwander, B., Amzal, B., Chen, F., Enas, N., Hobbs, B., Ibrahim, J. G., Kinnersley, N., Lindborg, S., et al. (2014) · Pharmaceutical Statistics · doi:10.1002/pst.1589 · Cited by 512
Nakagawa, M., Izumo, S., Ijichi, S., Kubota, H., Arimura, K., Kawabata, M., & Osame, M. (1995) · Journal of Neurovirology · doi:10.3109/13550289509111010 · Cited by 316 · cited 3×
“This observation is consistent with another previous finding that there are many patients with HAM/TSP who have Sjogren’s syndrome in Nagasaki [19] and in Kagoshima [15], the HTLV-1-endemic areas of Japan, suggesting a relationship between the pathogenesis of both diseases.”
BackgroundResultInfluentialHTLV-1-associated myelopathy/tropical spastic paraparesis
Bangham, C. R. M., Araujo, A., Yamano, Y., & Taylor, G. P. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.12 · Cited by 279
Self-citationYamano, Y., & Sato, T. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00389 · Cited by 204
Self-citationIzumo, S., Goto, I., Itoyama, Y., Okajima, T., Watanabe, S., Kuroda, Y., Araki, S., Mori, M., Nagataki, M., Matsukura, S., et al. (1996) · Neurology · doi:10.1212/wnl.46.4.1016 · Cited by 164
Therapeutic trials in 200 patients with HTLV-Iassociated myelopathy/tropical spastic paraparesis
Nakagawa, M., Nakahara, K., Maruyama, Y., Kawabata, M., Higuchi, I., Kubota, H., Izumo, S., Arimura, K., & Osame, M. (1996) · Journal of Neurovirology · doi:10.3109/13550289609146899 · Cited by 150
Yamanaka, H., Sugiyama, N., Inoue, E., Taniguchi, A., & Momohara, S. (2014) · Modern Rheumatology · doi:10.3109/14397595.2013.854059 · Cited by 147
Self-citationTaylor, G. P., Goon, P., Furukawa, Y., Green, H., Barfield, A., Mosley, A., Nose, H., Babiker, A., Rudge, P., Usuku, K., et al. (2006) · Retrovirology · doi:10.1186/1742-4690-3-63 · Cited by 117
Natural History of Human T-Lymphotropic Virus 1–Associated Myelopathy
Olindo, S., Cabre, P., Lézin, A., Merle, H., Saint-Vil, M., Signaté, A., Bonnan, M., Chalon, A., Magnani, L., Césaire, R., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.11.1560 · Cited by 110
Research works printed but not linked: 1
- Toyama N, Shiraki K. Epidemiological studies on varicella zoster in Miyazaki Prefecture. Infectious Agents Surveillance Report (IASR). 2013;34:298–300.
Cited by
Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019
Araujo, A., Bangham, C. R. M., Casseb, J., Gotuzzo, E., Jacobson, S., Martin, F., Penalva de Oliveira, A., Puccioni-Sohler, M., Taylor, G. P., & Yamano, Y. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000832 · Cited by 87
“Although interferon-α has been licensed for the treatment of HAM/TSP in Japan since January 2000 (whereas prednisolone is not licensed there), in a recent survey, only 2–3% of patients with HAM/TSP in Japan are currently treated with interferon.(8) The panel concluded that the quality of the evidence on efficacy was l…”
ResultSelf-citationClinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection
Legrand, N., McGregor, S., Bull, R. A., Bajis, S., Valencia, B. M., Ronnachit, A., Einsiedel, L. J., Gessain, A., Kaldor, J. M., & Martinello, M. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00078-21 · Cited by 96
“Based on limited data, HAU appears to occur in less than 1% of people with HTLV-1 infection (334, 335).”
BackgroundYamauchi, J., Araya, N., Yagishita, N., Sato, T., & Yamano, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107669 · Cited by 69
Self-citationHTLV-1 Infection and Rheumatic Diseases
Umekita, K., & Okayama, A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00152 · Cited by 36
Yamauchi, J., Tanabe, K., Sato, T., Nakagawa, M., Matsuura, E., Tsuboi, Y., Tamaki, K., Sakima, H., Ishihara, S., Ohta, Y., et al. (2022) · Viruses · doi:10.3390/v14010136 · Cited by 31
“Although data are limited, corticosteroids are most commonly used to maintain motor function by suppressing inflammation [4,6,7].”
BackgroundSelf-citation
Metadata
- Authors
- Tsutsumi, S., Sato, T., Yagishita, N., Yamauchi, J., Araya, N., Hasegawa, D., Nagasaka, M., Coler-Reilly, A. L. G., Inoue, E., Takata, A., & Yamano, Y.
- Affiliations
- St. Marianna University School of Medicine (JP)
- Corresponding author
- Yamano, Yoshihisa
- ORCID
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2019-10-21
- Volume
- 14
- Issue
- 1
- Pages
- 227-227
- ISSN
- 1750-1172 (ISSN-L)
- PMC
- PMC6802124
- OpenAlex
- W2980605760
- Cited by
- 33
- References
- 24
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 7 · 2023: 5 · 2022: 5 · 2021: 2 · 2020: 6
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Orphanet Journal of Rare Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Japan Agency for Medical Research and Development (JP19ek0109346, JP19ek0109356, JP19ek0109394)
- Ministry of Health, Labour and Welfare (19FC1007)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- HAM/TSP, tropical spastic paraparesis, comorbidities, medication use, oral corticosteroids, prednisolone, interferon-alpha, fracture, herpes zoster, uveitis, disease progression, rare disease registry, Japan
- MeSH terms
- Aged, Cross-Sectional Studies, Female, Humans, Japan, Male, Middle Aged, Retrospective Studies, Steroids, Human T-lymphotropic virus 1, Paraparesis, Tropical Spastic, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan. https://app.cochat.ai/papers/10.1186/s13023-019-1212-4
- The paper
- Tsutsumi, S., Sato, T., Yagishita, N., Yamauchi, J., Araya, N., Hasegawa, D., Nagasaka, M., Coler-Reilly, A. L. G., Inoue, E., Takata, A., & Yamano, Y. (2019). Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-019-1212-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.